bpc-157 compounding restrictions fda panel votes to place popular peptide on list Big win for $HIMS. The
Big win for $HIMS. The FDA advisory panel voted to allow compounding of BPC 157, KPV, TB 500 and MOTS C, opening the door to a multibillion dollar peptide market. Hims is positioned to capitalize. BPC 157 FDA Approval Status: Is It Approved for Human Use? FDA's Overreach on Compounded Peptides FDA may take an important step toward opening the peptide floodgates this week
Pay in 4 interest-free payments of $5.22 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 13 - Aug 18


